Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

Diabetes

Volumn 49, Issue 4, 2000, Pages 611-617

  Vella, Adrian ^a   Shah, Pankaj ^a   Basu, Rita ^a   Basu, Ananda ^a   Holst, Jens J ^b   Rizza, Robert A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; ISOPHANE INSULIN; SOMATOSTATIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; INSULIN RELEASE; INSULIN RESPONSE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 0034111103     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.4.611     Document Type: Article

References (42)

1. Weir GC, Mojsov S, Hendrick GK, Habener JF: Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
2. Larsson H, Holst JJ, Ahren B: Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422, 1997
3. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
4. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
5. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneillly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK: The insulinotropic actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74, 1994
6. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
7. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
8. Drucker DJ: Glucagon-like peptides. Diabetes 47:159-169, 1998
9. Byrne MM, Goke B: Human studies with glucagon-like-peptide-1 potential of the gut hormone for clinical use. Diabet Med 13:854-860, 1996
10. Villanueva-Penacarrillo ML, Alcantara Al, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
11. Merida E, Delgado E, Molina LM, Villanueva-Penacarillo ML, Valverde I: Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77:1654-1657, 1993
12. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, Perea A, Valverde I: Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183-189, 1995
13. Delgado E, Luque MA, Alcantara A, Trapote MA, Clemente F, Galera C, Valverde I, Villanueva-Penacarrillo ML: Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16:225-229, 1995
14. Morales M, Lopez-Delgado MI, Alcantara AI, Luque MA, Clemente F, Marquez L, Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarrillo ML, Valverde I: Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 46:1264-1269, 1997
15. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I: Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 139:2811-2817, 1998
16. Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, Tateishi K, Sato I, Schima K: Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism. 46:745-749, 1997
17. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075, 1994
18. Ghiglione M, Blasquez E, Uttenthal LO, de Diego JG, Alvarez E, George SK, Bloom SR: Glucagon-like peptide-1 does not have a role in hepatic carbohydrate metabolism. Diabetologia 28:920-921, 1985
19. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New Engl J Med 326:1316-1322, 1992
20. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A: Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053, 1999
21. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232, 1996
22. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404, 1998
23. Freyse EJ, Knospe S, Becher T, El Hag O, Goke B, Fischer U: Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism 48:134-137, 1999
24. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
25. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
26. D'Alessio DA, Prigeon RL, Ensinck JW: Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide I. Diabetes 44:1433-1437, 1995
27. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, Rizza RA: Impaired basal glucose effectiveness in NIDDM contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes 46:421-432, 1997
28. Butler PC, Caumo A, Zerman A, O'Brien PC, Cobelli C, Rizza RA: Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. Am J Physiol 264:E548-E560, 1993
29. Alzaid AA, Dinneen SF, Turk DJ, Caumo A, Cobelli C, Rizza RA: Assessment of insulin action and glucose effectiveness in diabetic and nondiabetic humans. J Clin Invest 94:2341-2348, 1994
30. Caumo A, Vicini P, Cobelli C: Is the minimal model too minimal? Diabetologia 39:997-1000, 1996
31. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA: Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97:2351-2361, 1996
32. Cobelli C, Toffolo G: Constant specific activity input allows reconstruction of endogenous glucose concentration in non-steady state. Am J Physiol 258:1037-1040, 1990
33. Hvidberg A, Toft-Nielsen MB, Hilsted J, Orskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78-107) amide on hepatic glucose production in healthy man. Metabolism 43:104-108, 1994
34. Bradley DC, Steil GM, Bergman RN: Quantitation of measurement error with optimal segments basis for adaptive time course smoothing. Am J Physiol 264:E902-E911, 1993
35. Steele R, Wall JS, De Bodo RC, Altszuler N, Kiang SP, Bjerknes C: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
36. Cobelli C, Pacini G, Toffolo G, Sacca L: Evaluation of insulin sensitivity and glucose clearance from minimal model: new insights from labeled IVGTT. Am J Physiol 250:591-598, 1986
37. Cobelli C, Bettini F, Caumo A, Quon MJ: Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodelling. Am J Physiol 275:1031-1036, 1998
38. Toft-Nielson M, Madsbad S, Holst JJ: The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
39. Wise SD, Nielsen MF, Cryer PE, Rizza RA: Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:2461-2469, 1998
40. Basu R, Basu A, Nielsen MF, Shah P, Rizza RA: Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus. J Clin Endocrinol Metab 84:2314-2319, 1999
41. Dinneen S, Miles JM, Rizza RA: Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest 91:2283-2290, 1993
42. Dinneen S, Alzaid A, Miles JM, Rizza RA: Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am J Physiol 268: 595-603, 1995